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Background: Total knee arthroplasty (TKA) is often associated
with a considerable amount of post-operative blood loss,
necessitating the transfusion of allogeneic blood, which can
add to the complications. Optimization of strategies to reduce
the need for blood transfusion is desired. This study was
designed to evaluate the efficacy of autologous platelet gel and
fibrin sealant in unilateral TKA.
Methods: Consecutive patients were operated on and assigned to
the study and control groups. Study group patients (n ¼ 85) were
operated on according to our standard TKA protocol, with the appli-
cation of autologous platelet gel and fibrin sealant on the wound
tissues at the end of surgery. Eighty patients were operated on
according to the same protocol, but without the use of platelet gel
and fibrin sealant, and served as the control group. All blood transfu-
sions, occurrence of wound leakage, wound healing disturbances
and incidences of post-operative infections were recorded.
Results: Patients in the treatment group had a significantly
higher post-operative haemoglobin level (11.3 vs. 8.9 g/dl,
respectively) and a decreased need for allogeneic blood products
(0.17 vs. 0.52 units, respectively) than those in the control group
(P < 0.001). The incidences of wound leakage and wound
healing disturbance were significantly less (P < 0.001) in
patients managed with platelet gel and fibrin sealant. Four
patients in the control group, who received blood products,
developed wound infection. The hospital stay was decreased
by 1.4  1.5 days for patients in the treatment group
(P < 0.001).
Conclusion: Peri-operatively applied platelet gel and fibrin
sealant may reduce the incidence of allogeneic blood
transfusions and complications associated with TKA.
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TOTAL knee arthroplasty (TKA) is often associatedwith a considerable amount of post-operative
blood loss, requiring allogeneic blood product
transfusions (ABPTs) (1, 2). However, the potential
health risks after ABPT include the development of
blood-borne diseases, leading to transfusion-related
non-infectious complications, and ABPTs contribute
to the incidence of immunosuppression, which may
lead to increased post-operative bacterial infection
rates (3—6). Finally, human error has been associated
with the administration of blood products, leading
to critical, even life-threatening, problems (7).
Increased awareness of these complications by
surgical teams has led to a continuous search for
blood conservation techniques in orthopaedic
surgery. Alternatives to avoid transfusions include
pre-operative autologous blood donation, epoetin
alpha (EPO), intravenous iron, non-steroidal
anti-inflammatory drugs, peri-operative haemodilu-
tion, intra-operative and post-operative blood cell
salvage and hypotensive anaesthesia (8—11).
However, these alternatives concentrate primarily
on decreasing post-operative blood loss and thus
avoiding the transfusion trigger. A more logical
blood management strategy would be to improve
haemostasis directly during and after surgery to
reduce post-operative blood loss and ABPT, and
improve wound healing, and, as a result, decrease
the incidence of post-operative infections.
Platelet gel (PG) is manufactured from platelet-
rich plasma (PRP), which is obtained after the
sequestration of a unit of autologous whole blood
with a blood cell separator. Treatment with PG
involves direct application of concentrated platelets
and their growth factors, specifically platelet-
derived growth factor (PDGF) and transforming
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growth factor-b (TGF-b), which have favourable
effects on the augmentation of the wound healing
cascade (12, 13). Fibrin sealants (FSs) have been
used in a variety of surgical specialities, such as
cardiothoracic surgery, cosmetic surgery and
neurosurgery, to reduce bleeding (14, 15). In
orthopaedic surgery, FSs have mainly been used as
reconstructive supportive surgical tools (16, 17). Only
a few publications have addressed the use of FS as a
haemostatic tool during TKA, and investigators in
these studies used a non-autologous cryoprecipitate-
based fibrinogen (18, 19). Our concept of peri-
operative blood management has involved the
exogenous application of PG and FS at the surgical
wound site. In this study, we evaluated the haemo-
static efficacy of sealing tissues, vessels and lymph-
atics by combining the use of both PG and FS in
patients undergoing primary TKA.
Materials and methods
Using a prospective observational study, we evaluated
165 patients who were scheduled for primary unilateral
TKA and who underwent the same surgical procedure.
The study was reported to the hospital ethical
committee and, prior to surgery, all study patients
were informed about the bloodmanagement procedure.
Initially, 80 patients, who served as controls, were
operated on without the use of blood management
techniques. Thereafter, 85 patients were operated on
and managed with our blood management protocol
consisting of PG and FS application (study group). All
patients were operated on consecutively. They all had
osteoarthritis of the knee and were operated on under
‘standard’ spinal anaesthesia by two surgeons using an
identical surgical protocol.
Blood management product preparation
Intra-operatively, after spinal anaesthesia had been
administered, approximately 350 ml of whole blood
was pre-donated from the median cubital vein into a
blood bag containing citrate for anti-coagulation. The
autologous blood was then centrifuged in a 125-ml
Latham bowl of the blood cell separator (Electa, Sorin
Group, Mirandola, Italy) in the operating room. The
blood cell separator sequestered the whole blood in a
semi-automatic controlled operating mode via a hard
spin at a g force of 1660. As a result, the whole blood
in the centrifuge was fractionated into blood compo-
nents, a process dependent on the weight of the
individual blood components. Initially, the platelet-
poor plasma (PPP) was evacuated from the whole
blood and separated from the buffy coat layer and
the erythrocytes. During this PPP release cycle, 20 ml
of the total PPP fraction was collected in a syringe for
application at the wound site. The remaining PPP
volume was collected in a blood bag and re-trans-
fused during wound closure. During the second
phase of the preparation process, the centrifuge was
slowed to a 350 g soft spin cycle to collect the buffy
coat layer, which consists of PRP and leucocytes
(Fig. 1). PRP was entirely collected in a 60-ml syr-
inge, and was totally used for PG application.
Finally, after the collection of PRP, the erythrocytes
were collected in a transfusion bag and were re-
infused to the patients during surgery at a time
determined by the anaesthesiologist.
The addition of thrombin and calcium chloride to
PPP results in the activation of the coagulation
cascade by converting the fibrinogen in PPP to
fibrin. This produces a stable fibrin cloth at the
wound site, independent of the patient’s
coagulation process, resembling the final pathway
of the physiological clothing cascade. PRP is also
activated with thrombin and calcium, forming a
viscous PG in which platelets subsequently
degranulate and release their platelet growth
factors.
Hard spin 1660 g
Soft spin 305 g
Platelet-poor plasma (PPP)
Buffy coat: Platelet-rich
plasma (PRP) and
leucocytes
Erythrocytes
Unit autologous whole blood
Fig. 1. Preparation of the blood components after autologous whole
blood pre-donation in the blood cell separator. One unit of whole
blood is separated first by a hard spin into platelet-poor plasma.
Thereafter, the soft spin centrifugation process evacuates the buffy
coat layer including platelet-rich plasma and leucocytes. Finally,
erythrocyte blood cells are collected separately in a re-transfusion
bag.
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In 85% of all patients treated with blood
management, we were able to produce autologous
thrombin (AT) to activate PRP and PPP. AT was
produced by mixing 8 ml of PRP with 0.35 ml of
calcium chloride 10% to antagonize the anti-coagu-
lative effect of the citrate present in the pre-donation
blood collection bag. This mixture was injected into
a glass Petri dish which activates platelets to form a
cloth. After 25—40 min, a cloth was formed inside
the glass dish. This cloth was manually squeezed
prior to PG and FS application. The cloth debris was
left behind in the dish and the liquid part,
containing AT (15—30 IU), was aspirated in a
syringe. PRP and PPP were activated with the
addition of AT at a ratio of 1 ml AT to 4 ml of
blood components.
In 12 patients, we were unable to produce AT, and
therefore had to use bovine thrombin (Thrombin-
JMI, GenTrac Incorporated, Middleton, WI) at a
concentration of 500 IU/ml to activate the blood
components (20). During the period of the study
(2002—2004), no restrictions with regard to the
activation of PRP or PPP with bovine thrombin
were effective in the Netherlands.
Operative procedure
Both cemented (Advantim and Advance, Wright
Medical Products, Arlington, TN and Somas, the
Netherlands) and non-cemented (LCS, Johnson
and Johnson DePuy, Piscataway, NJ) prostheses
were placed in a bloodless field with the use of
a pneumatic tourniquet. Haemostasis, after the
prosthesis had been inserted and the tourniquet
deflated, was performed with the use of electrocau-
tery of the major blood vessels. Before wound
closure, the knee soft tissues and joint were rinsed
with saline solution to remove all debris. In the
study group, the entire operative field was
thoroughly dried with gauze before 10 ml of PG
was initially injected in the back of the knee cavity,
the posterior recess, the gutters and the raw exposed
surfaces of the femur and tibia. The wound area was
retracted and FS was applied to the dried tissues by
a double syringe technique and delivered by aerosol
topical spraying (Aerosol Ratio Applicator,
Micromedics Inc, St. Paul MN) at a distance of
15 cm. The wound was closed in layers. After
closure of the knee capsula, another 10 ml of PG
was injected between the stitches on the repaired
extensor mechanism and the prepatellar fat. The
closed capsula and the subcutaneous tissues were
then sprayed again with FS. No wound drains were
used in the joints of patients in whom blood
management techniques were applied to prevent
evacuation of the PG, and thus the platelet growth
factors, via the wound drain. Control patients
received a wound drain as a routine measure.
After skin closure, a wound dressing and a
compressing bandage were applied.
The following data were obtained in both groups:
haemoglobin values were determined pre-opera-
tively, on the first, second, third and fourth post-
operative days and at hospital discharge. In the
blood management group, platelet and leucocyte
counts were performed pre-operatively and after
blood sequestration in PRP to assess the platelet
yield after the sequestration procedure.
The indication to give allogeneic blood products
in this study was a haemoglobin level of less than
8.8 g/dl to avoid oxygen transport deficiency which
might affect post-operative rehabilitation and
recovery. The number of homologous blood
products transfused, any wound complications,
wound dehiscence and signs of infection were
recorded.
All patients received thrombosis prophylaxis via a
subcutaneous injection of 20 mg nadroparin
(Fraxiparine), a low-molecular-weight heparin,
daily, before the operation until 6 weeks post-
operatively.
The primary objective of the study was to achieve
a decrease in ABPTs following TKA. Our second
objective was to monitor patient morbidity
parameters which affected the hospital length of
stay (e.g. joint function recovery, wound leakage,
infection and wound healing disturbances), as
judged by the ward physician. Wound leakage was
determined by moist wound dressings after the
second post-operative day. Wound healing
disturbances were defined as mild rubor with mild
oozing, but no skin dehiscence. After hospital
discharge, all patients went home.
Statistical methods
The study data were recorded on customized
patient tracking forms and entered into a
computerized database that allowed unbiased and
reliable data management. Statistical analysis
utilized SAS statistical software (SAS Institute,
Cary, NC, 2003). Categorical data were expressed
as percentages with 165 patients included, and
measured data were expressed as the mean  stan-
dard deviation.
Univariate analysis was performed using Fisher’s
exact test on all categorical data and Student’s t-test
on all measured data. Differences between means
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were analysed using Student’s t-test and
Satterthwaite’s approximation, which does not
assume equal variances. A two-sided P value of
0.05 or less was considered to be statistically
significant. To compare means from two
independent samples with n1 and n2 observations,
where m in this case is equal to zero:
t ¼ ðx1  x2Þ m
s
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n1
þ 1n2
q
The formula for Satterthwaite’s approximation
(21) for the degrees of freedom for the approximate
t statistic is:
d:f: ¼½fðw1 þ w2Þ2g=ðfðw21Þ=ðn1  1Þg þ fðw22Þ=
ðn2  1ÞgÞ
and provides a more conservative test of
significance than the standard t-test.
Results
The study group patients (n ¼ 85) and the control
group (n ¼ 80) were statistically homogeneous and
comparable, with the exception of the weight, which
was higher in the control group (Table 1).
The mean autologous pre-donation volume was
335 ml ( 28 ml). The sequestration process of the
blood cell separator resulted in an increase in platelet
and leucocyte counts by 453% and 177%, respectively,
when compared with baseline values (P < 0.001).
The mean number of post-operative blood
product transfusions was 0.17  0.6 in the blood
management treatment group compared with
0.52  0.9 in the control group (P < 0.001). With
regard to transfusion requirements, seven patients
(8.3%) in the blood management group received
transfusions (15 units of erythrocytes) compared
with 22 patients (27.5%) in the non-treated group
(42 units of red packed cells) (P < 0.001). The
majority of patients (68%) received two units, 9%
received more than three units and 22% received
one unit. All transfused patients met the criterion
to receive a blood transfusion.
The haemoglobin course is shown in Fig. 2. The
decrease in haemoglobin at post-operative days 1 and
2, relative to the baseline value, was significantly less in
the blood management group than in the control group
(P < 0.001 and P < 0.01, respectively).
At hospital discharge, all patients had a similar
haemoglobin value in the blood management group
(10.9  1.0 g/dl) and in the control group
(10.5  1.1 g/dl).
In the group receiving PG and FS, two patients
experienced wound leakage through their
bandages. However, no superficial wound healing
disturbances were seen in this group. In the control
group, 12 patients experienced wound leakage
(P < 0.001), and nine patients developed mild
wound healing disturbances, with a P value for the
difference of 0.001.
Superficial wound infections were observed in
four patients in the control group vs. zero patients
in the blood management group (P < 0.05). These
comorbidity factors were associated with the total
length of hospital stay, which was significantly
shorter in the blood management group
(6.9  1.4 days) than in the control group
(8.3  2.9 days) (P < 0.001).
Table 1
Patient characteristics and type of knee prosthesis used.
Description Treatment
group (n ¼ 85)
Control
group (n ¼ 80)
Age (years) 69.4  9.1 67.4  9.9
Gender (female/male) 58/27 58/22
Mean weight (kg) 74.0  10.7 80.5  13.3*
Pre-operative
haemoglobin (g/dl)
13.6  1.1 13.7  1.1
Cemented (%) 74 73
The values are given as the mean  standard deviation.
*P < 0.05, the mean weight was significantly higher in the control
group.
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Fig. 2. Mean haemoglobin values for the treatment group and
control group vs. the post-operative day (PO-1—4). *P < 0.001, a
decrease in the haemoglobin loss for treated patients at PO-1 and
PO-2.
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Discussion
TKA is associated with major blood loss. In this
study, it was found that the application of PG and
FS during TKA reduced significantly the need for
allogeneic blood transfusions when compared with
that required in control patients, using the same
criteria for transfusion in both groups, although
the average body weight, and thus the red blood
cell mass, of the patients in the blood management
group was significantly lower than that in the
control patients. The decrease in haemoglobin and
the need for blood transfusions in control patients
were comparable with the data reported by others
(1, 11). All transfusions were given on the first post-
operative day.
The literature on FSs clearly shows improved
haemostatic effects in both animal and human
models (15); however, only a few similar clinical stu-
dies have been performed during TKA, and have
shown results comparable to those obtained when
haemostatic agents are used to control bleeding.
Levy et al. (18) showed a decrease in blood loss and
reduced blood transfusion requirements when using
Quixil (Omrix Biopharmaceuticals SA, Brussels,
Belgium), which he applied by topical spraying. In a
multicentre, randomized controlled trial by Wang
et al. (19), the same FS was used, and the decrease in
haemoglobin level was almost 29% less in the FS
group than in the control group. In comparison with
the above-mentioned studies, our blood management
protocol involved the production of both autologous
FS and PG. Activated PPP was sprayed as a tissue
sealant on the edges of the sawn bones and soft tis-
sues to avoid blood loss. Furthermore, FS may inhibit
the inflammatory response, with less adhesion
formation, as demonstrated by Jahoda et al. (22). It
has been postulated that this decrease in inflamma-
tion may contribute to a lower tissue reaction, thus
leading to fewer adhesions (23). Studies byMarx et al.
(24) have confirmed the efficacy of concentrating pla-
telets by centrifugation ofwhole blood and harvesting
PRP. PG with a platelet concentration three to six
times that of the native platelet concentration will
release, amongst others, the platelet growth factors
PDGF and TGF-b, which play a pivotal role in the
wound healing process (12, 13). As PRP is a buffy coat
product, it also contains a high concentration of leu-
cocytes and, in particular, granulocytic neutrophils
which contain myeloperoxidase (MPO), a substance
known to remove bacteria (25). It may be speculated,
therefore, that PG may also have anti-bactericidal
properties.
Twelve patients required bovine thrombin
because the autologously prepared thrombin failed
to set up a firm gel. In the USA, bovine thrombin is
still the PRP activator of choice to produce PG (26).
However, at present, we have discarded the use of
bovine thrombin in order to avoid the potential
development of antibodies to clotting factors V and
XI and thrombin, which might occasionally lead to
life-threatening coagulopathies (27). The analysis of
the study parameters from these patients did not
reveal any differences in outcome relative to the
patients treated with AT.
Blood loss in TKA occurs mainly after surgery, as
the procedure is performed with the use of a
pneumatic tourniquet. Because our primary
objective was to reduce post-operative blood loss
by means of peri-operative blood management
techniques, the use of post-operative drainage and
re-infusion of unwashed shed blood was obsolete.
Furthermore, there is reasonable concern about the
quality of unwashed re-transfused wound blood
(28). It has also been argued that the use of FSs
during joint replacement may be unnecessary
because of autologous pre-donation techniques to
compensate for post-operative blood loss.
Although autologous pre-donated blood is not
associated with the risks of viral disease
transmission and immunomodulatory changes, the
incidence of administrative transfusion errors and
bacterial overgrowth is comparable with that when
using homologous transfused blood (7, 29).
Furthermore, a special blood banking protocol and
schedule to pre-donate prior to surgery is required
and certain patients are unable to donate blood.
Increasing the pre-operative haemoglobin value
through pre-operative EPO injections, in order to
minimize the number of ABPTs by avoiding the
transfusion trigger, has become more popular.
However, the aim of our blood management
concept is to avoid post-operative blood loss and
to use the patient’s own blood components to
support the healing process. Furthermore, the costs
of EPO outweigh those of our blood management
programme. Our control patients received a wound
drain. The orthopaedic surgeons did not use a post-
operative drain in the study patients to prevent PG,
and therefore platelet growth factors, being
removed from the wound cavity. No differences
were seen with regard to leg swelling and return
of active function of the quadriceps muscle between
treated and control patients. This finding is in
accordance with the observations of several other
authors, indicating that there is no difference in
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post-operative outcome when drained and non-
drained patients are compared with regard to leg
swelling, wound disturbances, return of function
and wound leakage (30).
This study showed that there was a significant
decrease in the incidence of wound leakage and
wound healing disturbances in patients treated
with PG and FS. The decreased leakage is most
probably the result of the efficacy of FS in sealing
the oozing soft tissue wound sites and of the ability
of PG to plug the bone marrow sinusoids at the cut
bone sites in the knee cavity and at surrounding
sawn bone tissues in the femur and tibia next to
the prosthesis. The reduced wound leakage
presumably results in decreased wound healing
disturbances, and wound healing is further
supported by the growth factors released from PG.
Four patients in our control group received two
units of allogeneic blood and developed a
superficial wound infection which was treated
with antibiotic therapy. None of the treated patients
showed signs and symptoms of infection. Another
explanation for the development of these wound
infections could be the increased allogeneic
transfusion rate in the control group. Our findings
are in accordance with the data of Thomas et al. (11)
and with the data from almost 4000 patients in the
Orthopedic Surgery Transfusion Hemoglobin
European Overview (OSTHEO) study, which
showed that more than 4% of allogeneic transfused
patients developed a wound infection (31). In a meta
analysis, Hill et al. showed that allogeneic blood trans-
fusions are associated with transfusion-associated
immunomodulation, and that transfusions are an
important risk factor for the development of post-
operative bacterial infections (6). In addition, ABPT
may lead to a decrease in pro-angiogenic factors (e.g.
interleukin-8) that are essential for wound healing (32).
Although we attempted to reduce, as much as
possible, confounding factors in our study (same
anaesthetic technique, one type of blood cell separa-
tor and limited number of surgeons), the effect of
varying platelet and fibrinogen concentrations was
not studied. The study was not sufficiently powerful
to demonstrate whether different concentrations of
platelets and fibrinogen had an effect on
haemoglobin loss and thus erythrocyte transfusions.
In conclusion, in patients undergoing TKA, we
demonstrated that the exogenous application of PG
and FS to the wound site supported the haemostatic
condition with the delivery of concentrated platelet
growth factors and leucocytes. This resulted in a
decreased blood transfusion requirement, lower
incidence of post-operative wound healing
disturbances, less infections and a shorter length of
hospital stay. Future studies should aim to elucidate
the potential anti-bactericidal effect of PG, to
demonstrate the economic costs and benefits and
to address logistic problems in performing these
blood management techniques, not only during
TKA but potentially also in other orthopaedic
surgeries.
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